Compass Pathways Announces Publication of Results from Phase 2 Study of COMP360 Psilocybin for Post-Traumatic Stress Disorder
(NASDAQ:CMPS) LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovati...